Early demand signals a shift toward flexible GLP-1 benefit models that help employers support employee access and transparent costs
Brief Summary:
GoodRx Employer Direct weight loss offering is now
New $24.99 monthly plan includes a primary member and up to four dependents, including children, adults, and pets, with more than 250 generic medications available for free and savings on dental, vision, lab and
Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year
Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we,"
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results
New $14.99-per-month membership brings together free and low-cost generic medications, affordable online care visits, and savings across dental, vision, labs and imaging
Brief Summary:
GoodRx launched GoodRx
Pharma Direct Revenue Increased 82% Year-Over-Year in the First Quarter
Company Raises Full Year 2026 Revenue and Adjusted EBITDA Expectations
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us,"
Eligible self-pay patients can access the oral diabetes treatment for as low as $149 per month
Brief Summary:
GoodRx expands access to Ozempic® pill (oral semaglutide) for as low as $149 per month
Available
GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets
Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss
Brief Summary:
Wegovy® HD is now available on GoodRx at a self-pay price of $399
Eligible self-pay consumers can access Foundayo starting at $149 per month through GoodRx
Brief Summary:
GoodRx is expanding access to the newly FDA-approved oral GLP-1 medication, Foundayo™
Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc®
GoodRx (NASDAQ:GDRX), the leading platform for
GoodRx Employer Direct enables self-insured employers to subsidize the $449 Lilly Employer Connect medication price for Zepbound KwikPen to reduce employee out-of-pocket costs
Brief Summary:
GoodRx to collaborate
New program combines employer-subsidized discounted cash prices and custom telemedicine solutions with existing health benefits to close coverage gaps and support access to high-impact medications
GoodRx
Brief Summary:
GoodRx is a core integration partner for TrumpRx, powering the pricing for leading brand medications
At launch, GoodRx is the integrated pricing source on TrumpRx for Pfizer, including over 30 of
Independent assessment validates GoodRx's continued leadership in cybersecurity and data protection
GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced it has earned its
